Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Flaherty KR, et al. Among authors: coeck c. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. N Engl J Med. 2019. PMID: 31566307 Clinical Trial.
A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.
Joos GF, Aumann JL, Coeck C, Korducki L, Hamilton AL, Kunz C, Aalbers R. Joos GF, et al. Among authors: coeck c. Respir Med. 2015 May;109(5):606-15. doi: 10.1016/j.rmed.2015.02.005. Epub 2015 Feb 14. Respir Med. 2015. PMID: 25776199 Free article. Clinical Trial.
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, Varga J, Coeck C, Gahlemann M, Sauter W, Schmidt H, Highland KB; SENSCIS™ trial investigators. Distler O, et al. Among authors: coeck c. Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):75-81. Epub 2017 Jun 29. Clin Exp Rheumatol. 2017. PMID: 28664834 Free article. Clinical Trial.
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
Cottin V, Richeldi L, Rosas I, Otaola M, Song JW, Tomassetti S, Wijsenbeek M, Schmitz M, Coeck C, Stowasser S, Schlenker-Herceg R, Kolb M; INBUILD Trial Investigators. Cottin V, et al. Among authors: coeck c. Respir Res. 2021 Mar 16;22(1):84. doi: 10.1186/s12931-021-01668-1. Respir Res. 2021. PMID: 33726766 Free PMC article. Clinical Trial.
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD).
Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Coeck C, Schlecker C, Voss F, Wachtlin D, Martinez FJ. Maher TM, et al. Among authors: coeck c. BMJ Open Respir Res. 2023 Sep;10(1):e001580. doi: 10.1136/bmjresp-2022-001580. BMJ Open Respir Res. 2023. PMID: 37709661 Free PMC article. Clinical Trial.
Objective measurement of cough in pulmonary fibrosis: a cohort study - ImpaCT.
Kebbe J, Hart SP, Kaner RJ, Kulkarni T, Wollin L, Coeck C, Vinisko R, Patel N, Wijsenbeek MS. Kebbe J, et al. Among authors: coeck c. ERJ Open Res. 2024 Sep 30;10(5):00310-2024. doi: 10.1183/23120541.00310-2024. eCollection 2024 Sep. ERJ Open Res. 2024. PMID: 39351380 Free PMC article.
ACTH and cortisol levels during residency training.
Coeck C, Jorens PG, Vandevivere J, Mahler C. Coeck C, et al. N Engl J Med. 1991 Sep 5;325(10):738. doi: 10.1056/NEJM199109053251016. N Engl J Med. 1991. PMID: 1651455 No abstract available.
11 results